Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03770429 · ClinicalTrials.gov registry record · Phase 1
AZD6738 for Patients With Progressive MDS or CMML
A Phase 1 study of Leukemia and Myelodysplastic Syndrome, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 4
- Study locations
NCT03770429 is a Phase 1 study of Leukemia and Myelodysplastic Syndrome that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 52 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT03770429, a Phase 1 study of Leukemia and Myelodysplastic Syndrome, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .
Conditions Studied
Interventions
- DRUG AZD6738
Study Locations (4)
Massachusetts
- BIDMC - Boston
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital Cancer Center - Boston
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03770429
The ClinicalTrials.gov registry entry for NCT03770429 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (89% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which AZD6738 is the first listed.
NCT03770429 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT03770429 about?
NCT03770429 is a clinical study titled "AZD6738 for Patients With Progressive MDS or CMML". This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .
What is the current status of trial NCT03770429?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2019-08-05. Estimated completion is 2026-05-31.
What conditions does trial NCT03770429 study?
This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndrome.
What interventions are being tested in trial NCT03770429?
The interventions under investigation include: AZD6738 (DRUG).
Who is sponsoring clinical trial NCT03770429?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03770429 being conducted?
This trial has 4 study locations across Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.